3 367

Cited 25 times in

Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection

Authors
 Jong Won Choi  ;  Jun Yong Park  ;  Sang Hoon Ahn  ;  Ki Tae Yoon  ;  Heung-kyu Ko  ;  Do Yun Lee  ;  Jong Tae Lee  ;  Kyung Sik Kim  ;  Jin Sub Choi  ;  Kwang-Hyub Han  ;  Chae Yoon Chon  ;  Do Young Kim 
Citation
 AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, Vol.32(6) : 564-569, 2009 
Journal Title
 AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 
ISSN
 0277-3732 
Issue Date
2009
MeSH
Antineoplastic Agents/administration & dosage* ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/therapy* ; Chemoembolization, Therapeutic* ; Female ; Humans ; Liver Neoplasms/pathology ; Liver Neoplasms/therapy* ; Male ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/therapy* ; Neoplasm Staging ; Prognosis ; Safety ; Survival Rate ; Treatment Outcome
Keywords
hepatocellular carcinoma ; transarterial chemoembolization ; recurrence
Abstract
OBJECTIVES: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after curative resection and to examine the factors associated with the prognosis in a single center. METHODS: Between January 1995 and July 2006, 169 patients who had undergone curative resection were diagnosed with recurrent HCC. Of these, 114 patients underwent TACE as first-line therapy and were followed until July 2007. RESULTS: At the time of resection, the mean tumor size was 4.8 + or - 2.9 cm, and 96 (84.2%) patients had a single tumor. Single nodular recurrence was observed in 53 (46.5%) patients. The mean size of the recurrent HCC was 2.1 + or - 1.2 cm. The disease-free survival after TACE was 46.0%, 16.7%, and 13.4% at 1, 2, and 3 years, respectively. The overall survival after TACE was 77.8%, 53.6%, and 31.6% at 1, 3, and 5 years, respectively. Cox regression analysis revealed that the Edmonson grade and time to recurrence (>6 months) independently affected the disease-free survival (both P < 0.05). The time to recurrence (>6 months) and tumor-node-metastasis stage were associated with overall survival (both P < 0.05). Only 1 lethal complication (biliary sepsis) occurred after TACE. CONCLUSIONS: TACE seems to be a safe, effective treatment for recurrent HCC after curative resection
Full Text
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00000421-200912000-00002&LSLINK=80&D=ovft
DOI
10.1097/COC.0b013e3181967da0
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Ko, Heung Kyu(고흥규)
Kim, Kyung Sik(김경식) ORCID logo https://orcid.org/0000-0001-9498-284X
Kim, Do Young(김도영)
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Yoon, Ki Tae(윤기태)
Lee, Do Yun(이도연)
Lee, Jong Tae(이종태)
Chon, Chae Yoon(전재윤)
Choi, Jong Won(최종원)
Choi, Jin Sub(최진섭)
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/105535
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse